Genotype and immunophenotype can be used to define biological species of acute lymphoblastic leukemia (ALL). The purpose of these two pilot studies, conducted between 1986 and 1994, was to explore the feasibility and acceptability of classifying ALL in this manner for selection of treatment rather than using conventional risk for failure factors such as age and initial white blood cell count. The possibility that conventional risk factors would be overcome and survival improved by this approach was also considered. Flow cytometry and chromosome analysis were used to classify the ALL of 150 children into one of five biologic categories as defined by cell surface antigens, DNA index and chromosome number and arrangement. Chemotherapy regimens depended on the assigned category. There was no provision for cranial irradiation and use of alkylating agents, anthracyclines and epipodophyllotoxins was restricted in order to reduce risk of late adverse sequelae. All patients are included in the analysis regardless of presenting condition or adherence to protocol. The majority of patients were Mexican-American or African-American. Eight-year event-free survival (EFS) is 60.7% (±4%) and 8-year overall survival (OAS) 72.6% (±3.7%). EFS and OAS varied significantly among the biologic categories despite differences in chemotherapy regimens. When the patients with B-precursor ALL were retrospectively classified by current Pediatric Oncology Group (POG) criteria, 8-year EFS was 82% (±7.3%) for the good risk group, 68.9% (±5.9%) for the standard risk and 48.8% (±7.6%) for the poor risk, all significant differences. However, when retrospectively classified according to the Rome/NCI prognostic criteria the 8-year EFS for standard risk patients was 69.1% (±5.1%) and for high risk 58.8% (±6.9%), not a statistically significant difference. Numbers of T cell and B cell patients are too few for comparison. Gender and ethnicity influenced survival as in treatment based on prognostic factors. Initial central nervous system (CNS) relapse occurred in five patients (3%) and combined CNS and hematological relapse in six (3%). Factors significantly associated with CNS and combined relapse were leukemic pleocytosis in the initial CSF sample, pro-B immunophenotype and DNA index Ͻ1.16, but not initial white blood cell count. Only three survivors appear to have serious late adverse sequelae, the only neurologic the result of asparaginase-induced cortical vein thrombosis. The results suggest that use of biologic species as defined by immunophenotype and genotype to select therapy of ALL is feasible and acceptable but under the conditions of these studies offered no apparent therapeutic advantage over conventional risk grouping. However, the introduction of molecular genotyping and novel gene targeted therapeutic agents justify further exploration of this approach. Leukemia (2000) 14, 1354-1361.
ment failure and to determine treatment. 1 The advent of immunophenotyping led to further risk assignment of ALL by cell surface characteristics. 2 When measurement of DNA index and karyotypic analysis of ALL revealed prognosisrelated variations in number and arrangements of chromosomes, genotype became an additional factor. [3] [4] [5] [6] Based on the concept that genotype and immunophenotype defined species of ALL and might be better measures of biology and curative response to therapy than conventional risk features, a series of two pilot studies were initiated in 1986. Their purpose was to explore the clinical feasibility and acceptability of this approach to classification and treatment selection and to look for evidence suggestive of a therapeutic advantage. Their background and rationale have been described previously, as well as their preliminary results. [7] [8] [9] Before the studies were initiated, criteria were established for deciding whether the results might suggest a therapeutic advantage to this approach: significant improvement in EFS and cure rates by historical comparison; similar outcome among the five biologic categories; and similar outcome regardless of POG risk group, ethnicity and gender. None of these criteria were met but the small numbers of patients in each category, frequently unsuccessful chromosome analyses, and lack of molecular genotyping to identify cryptic gene rearrangements compromise interpretation.
Cranial irradiation was excluded from the treatment regimens because of evidence that intensive systemic and intrathecal chemotherapy is equally effective in preventing CNS relapse and in order to avoid the adverse effects of brain irradiation. 10 Use of anthracyclines, alkylating agents and epipodophyllotoxins was restricted in order to limit their welldescribed sequelae.
The purpose of this communication is to present a final analysis of the results of these studies 5 years after their closure to new registrants.
Patients and methods

Patients
One hundred and fifty children with newly diagnosed, previously untreated ALL were admitted to these two pilot studies between 22 December 1986 and 29 November 1994 at MD Anderson Cancer Center, Houston, and Driscoll Children's Hospital, Corpus Christi. Seventy-nine were boys and 71 girls. Ages ranged from 7 months to 161 years. Their initial white blood cell counts (WBC) varied from 0.5 to 894 × 10 9 /l with a median of 13.2 × 10 9 /l. Family surnames, self identification, and family histories were used to determine ethnicity. The term Mexican-American was used for children living in the United States who have Mexican ancestry. The term LatinAmerican was used for children referred from Mexico and Central and South America. Sixty-four children were Mexican-American, 59 were European-American, 11 were Latin-American and 10 African-American. Six were from countries in Asia and Europe. Since both hospitals provide care to all Texas residents without regard for ability to pay there was no socio-economic bias in accession of Texas patients.
Informed parental consent and when feasible, informed child assent were obtained prior to registration in these studies. One patient had fatal sepsis on admission, 11 were nonadherent to the treatment protocol and seven were suspected to be non-adherent. However, all registered patients are included in the data analysis regardless of initial condition or adherence to protocol. Patients whose treatment was stopped prematurely or compromised by non-adherence were continued in the study and not censored at the time of cessation or compromise.
Patient evaluation included bone marrow examination for morphology and cytochemistry and flow cytometry of leukemia cells for surface markers and DNA index. Short-term cultures of the cells were used for chromosomal analysis with G-banding. Direct preparations were not usually performed. Forty-six patients were registered on the first pilot study, P8609, from December 1986 to September 1989. One hundred and four patients were admitted to the second pilot study, P8904, from November 1989 to November 1994.
Classification
Patients were classified in accordance with their leukemia genotype as determined by DNA index and cytogenetics and by cell surface markers as defined by flow cytometry. During the first study, P8609, patients with T cell or B cell ALL were committed to other studies, while in the second, P8904, they were included. While the criteria for classification were somewhat different for the two studies, reflecting advances in technology and new information, they can be condensed as in Table 1 . In broad terms using current terminology, category A represents early pre-B ALL, B is pro-B ALL, C is pre-B or early pre-B ALL with pseudodiploidy, D is T cell ALL and E is B cell ALL. The classification method was as follows. Bone marrow aspirates were obtained at diagnosis and sent for diagnostic studies as mentioned above. Remission induction therapy was instituted simultaneously and once all data were available, usually within 4 to 5 days, patients were assigned to categories. When chromosome analysis was unsuccessful, DNA In three cases only CD5 and CD7 were positive and in one only CD2 and CD5.
Leukemia index was used to identify hyperdiploidy (category A). Otherwise, when chromosome analysis and DNA index determination were unsuccessful, patients were assigned in accordance with immunophenotype alone: those with DR, CD10, CD19 positivity were assigned to category A, with DR, CD19 positivity and CD10 negativity to B, and with DR, CD10, CD19 and cytoplasmic immunoglobulin positivity to C. Patients whose ALL had thymic cell surface antigens were assigned to D, and those whose ALL cells displayed surface immunoglobulin to E.
Treatment protocols
Both pilot studies and their consent forms were reviewed and approved by the Surveillance Committee of the MD Anderson Cancer Center prior to registration of patients. Study protocols are available on request and only brief summaries are given here and in Table 2 . In P8609 study, a 6-week remission induction using prednisone, vincristine, asparaginase, mercaptopurine and three-drug intrathecal therapy (methotrexate, cytarabine, hydrocortisone) was followed by 2 to 2. years of continuation therapy with weekly methotrexate, daily mercaptopurine, periodic pulses of prednisone, vincristine and asparaginase, and periodic triple intrathecal therapy. In addition, category A patients received periodic high-dose intravenous methotrexate infusions, category B etoposide plus cytarabine, and category C high-dose methotrexate, cyclophosphamide Triple IT was given at least one week apart from systemic Mtx or Ara-C.
and cytarabine. As indicated above, category D and E patients were committed to other studies during this time period. In P8904 study, remission induction was limited to 4 weeks and mercaptopurine was deleted during induction. For category D, daunorubicin was included and for category E highdose cyclophosphamide was included. During continuation therapy, category A patients received high-dose mercaptopurine infusions following the high-dose methotrexate infusions. Category B chemotherapy was unchanged from the P8609 study. Category C patients received rotating cycles of high-dose methotrexate plus high-dose cytarabine, high-dose methotrexate plus high-dose mercaptopurine, and high-dose cyclophosphamide. Category D patients received rotating cycles of intravenous combinations of cyclophosphamide and cytarabine, daunomycin and cytarabine, vincristine and etoposide and periodic triple intrathecal drugs. Category E patients received rotating cycles of high-dose intravenous cyclophosphamide, high-dose cytarabine, and high-dose methotrexate plus high-dose mercaptopurine, and more closely spaced triple intrathecal therapy. Initially the chemotherapy schedule was shortened to 25 months for category A patients and 19 months for B and C, but later extended by 6 months for each of the three categories. Category D patients were scheduled for 18 months and E for 6 months. Chemotherapy delays due to toxicity resulted in longer durations of actual treatment.
Drug dosage was adjusted to provide maximum tolerated chemotherapy and to avoid unacceptable toxicity when possible. Total daunorubicin dosage was limited to 200-250 mg/m 2 . During conventional daily mercaptopurine and weekly methotrexate treatment, we attempted to maintain the white blood cell count less than 2.0 × 10 9 /l and the mean corpuscular volume of red blood cells above 95 fl.
No provision was made for central nervous system irradiation in these studies. A standard method for dosage, preparation and administration of triple intrathecal therapy was used. 10 It was given on days 1, 8, 22 and 36 and subsequently throughout continuation chemotherapy, every 8 weeks for categories A and B, every 6 weeks for category C, every 5 weeks for category D and every 3 weeks for category E. Total numbers of planned intrathecal treatments were 16 to 20 for category A patients, 13 to 16 for category B and 16 to 20 for category C. The differences were due to variations in length of continuation therapy, as indicated above. Twenty intrathecal treatments were planned for category D patients and 12 for those in category E. Because of anecdotal concerns about neurotoxicity, intrathecal therapy was administered at least 1 week apart from systemic methotrexate or cytarabine.
Specific and supportive care, including drugs and hospitalization, were provided to all patients by the same staff in the same facilities without regard to ethnicity or ability to pay. Bone marrow studies were performed at diagnosis, at remission, at completion of therapy, at 3 months after completion of therapy, and on clinical indication.
Cerebrospinal fluid was examined at diagnosis, at each intrathecal therapy, at completion of therapy and on indication. POG criteria for remission, relapse, CNS status and toxicity were used as described in the ALINC 16 classification protocol. Follow-up studies included evaluation of growth and development and neuropsychological and endocrine status.
Statistical analysis
Since these were pilot studies without randomized comparison and numbers in each treatment category were relatively small, statistical analysis was limited. The Graphpad Software, Prism 201 package was used to determine Kaplan-Meier plots of overall survival (OAS) and event-free survival (EFS) for the entire group of patients, and to compare EFS by treatment category, ethnicity and gender using the log rank test. Patients with B-precursor ALL were retrospectively classified by the Rome/NCI prognostic risk grouping 11, 12 and the current POG risk classification, 12 which more closely resembles the biologic categorization used in our studies. The same statistical methodology was used to plot and compare EFS of the patients retrospectively classified by the Rome/NCI and POG risk criteria.
The Rome/NCI method stratifies patients as standard risk if they are ages 1 to 9.9 years and have initial WBC less than 50 × 10 9 /l; all others are considered high risk for treatment failure. For B-precursor ALL over age 1 year, POG classifies patients ages 1 to 10 years with initial WBC of less than 50 × 10 9 /l at diagnosis as good risk. Those age 10 to 21 years, or with initial WBC of 50 × 10 9 /l or more, or with evidence of central nervous system or testicular involvement are classified as poor risk. At day 28, the grouping is modified in accordance with results of further studies. Those initially classified as good risk are continued as good risk if hyperdiploidy (DNA index Ͼ1.16) or trisomy 4 and 10 are found. Those initially classified as poor risk remain poor risk if unfavorable cytogenetics, namely t(1;19), t(4;11) or t(9;22) are found, if DNA index is р1.16 or unsatisfactory, and trisomy 4 and 10 are not identified. The remainder of the patients are considered 'standard risk'. POG uses separate treatment protocols for each of these three risk groups. POG also uses separate protocols for T cell ALL (our category D), B cell ALL (our category E) and for ALL in infants less than 1 year of age, many of whom would be in our category B because infant ALL is often DR and CD19 positive and CD10 negative (pro-B) and/or demonstrates a chromosomal translocation involving band 11q23. 13 Fisher's exact test, two-sided, 95% confidence interval, was used to determine the significance of factors associated with CNS relapse. No attempt was made at multivariate analysis because of the small numbers of patients and the many variables. Estimated OAS and EFS values are reported in percentages plus or minus one standard error of the mean (s.e.m.). The cut-off point for data analysis was 1 February 2000.
Results
Classification of leukemia
Success in chromosomal analysis improved as the studies progressed. Satisfactory chromosomal preparations were achieved with bone marrow leukemia cells of 113 patients (75.3%). Forty-eight were diploid and 31 hyperdiploid. Twenty-three revealed translocations, including three t(9;22), two t(1;19), one t(4;11), one t(9;11), one t(8;14) and one t(8;22), non-random recurring chromosome rearrangements now known to be highly significant. Hypodiploidy was found in cells of two patients and near tetraploidy in another. Four children had Down syndrome, one had Klinefelter syndrome and three had trisomies of unestablished significance. Neither fluorescent in situ hybridization (FISH) nor molecular genotyping by Southern blot or polymerase chain reaction (PCR) was available during these studies. This lack plus the 25% failure to obtain satisfactory chromosomal analysis make it likely that significant genetic abnormalities went undetected in many patients, particularly t(12;21) with formation of the novel TEL-AML fusion gene, the most frequent in childhood ALL. 13 DNA index measurements were successful in 135 (90%) of patients. They were 1.0 in 88 patients, у1. 16 
Treatment failures (Table 3)
One hundred and forty-five of the 150 (97%) patients registered developed complete remission after induction treatment. Of the five who did not, one died of bacterial cellulitis and sepsis shortly after admission and four failed to enter remission, two with massive visceral leukemia and extreme leukocytosis. One child died during remission from adenovirus and cytomegalovirus pneumonia. The remissions of three children were ended by secondary acute myeloid leukemia (AML), two with T cell ALL who had received etoposide, cyclophosphamide and daunorubicin and one with pro-B ALL who had received etoposide.
Five children had isolated CNS relapse and six had simultaneous CNS and hematologic relapse. Two children with isolated CNS relapse and one with combined relapse had CNS 2 status (Ͻ5 WBC/l, leukemia cells) at diagnosis; two with combined relapse had CNS 3 status (Ͼ5 WBC/l, leukemia cells and/or cranial nerve or orbital involvement) initially. The other six, three with isolated and three with combined relapse, had CNS 1 status (Ͻ5 WBC/l, no leukemia cells). Of the 145 patients with successful remission induction, six of 126 (4.8%) with initial CNS 1 status developed CNS relapse or combined CNS and hematological relapse, three of 15 with CNS 2 status, and two of four with CNS 3 status. Only one patient received preventive CNS radiation in these studies: a 15-year-old youth with CNS 2 status at diagnosis who received cranial radiation at the end of chemotherapy because of rare leukemia cells in the CSF at month 24 of treatment. Table 4 summarizes some presenting features of the children who developed CNS relapse. These were compared with corresponding features of the patients who did not develop Leukemia CNS relapse and for whom similar data are available. By Fisher's exact test there was an association of isolated or combined CNS relapse with initial CNS 3 status (P = 0.0007), pro-B immunophenotype (P = 0.001), and DNA index Ͻ1.16 (P = 0.036). Association with age Ͻ10 years (P = 0.067) and initial CNS 2 status (P = 0.09) was only suggestive. There was no association with WBC Ͼ10 × 10 9 /l (P = 1.0) or WBC Ͼ50 × 10 9 /l (P = 0.70), and marginal association with WBC Ͼ100 × 10 9 /l (P = 0.10). Multivariate analysis was not attempted because of the small number of patients with CNS relapse and the heterogeneity of their leukemias and their treatments.
For the children who completed chemotherapy in remission, the subsequent relapse rate was twice as high in those with less than 24 months total duration of chemotherapy. The shorter duration of chemotherapy was also associated with the classification categories that had higher relapse rates so that one cannot conclude whether it was the species of ALL, the duration of treatment or both that were responsible.
Toxicity
Most patients (94%) experienced NCI grade 3 to 4 hematologic toxicity because severe hematosuppression was used as a parameter of adequacy of chemotherapy. Forty-seven developed asparaginase sensitivity, 21 severe infection, 17 severe hepatic toxicity, 15 serious metabolic disorders, 10 severe gastrointestinal toxicity, and 17 severe neurological disorders, mostly related to methotrexate or vincristine administration. One child died of severe viral pneumonia during remission and three developed secondary AML. All children recovered from hematosuppression and the allergic, metabolic and gastrointestinal toxicities and all but one from neurological toxicity. This child developed cortical vein thrombosis after asparaginase and has a personality change. Hepatic toxicity was reversible except in one child who has persistent hepatitis C. One child with asparaginase-induced pancreatitis and one with chemotherapy-related thrombotic thrombocytopenic purpura fully recovered. One child, extremely obese at diagnosis, is disabled with osteonecrosis. No cardiac toxicity has been noted in the six survivors who received daunorubicin.
Survival
In calculating and comparing survivals, all patients are included in the data analysis regardless of initial condition or adherence to protocol, as noted previously. This includes one patient with fatal sepsis on admission, 11 non-adherent patients and seven suspected to be non-adherent to protocol.
For the 150 children registered in these studies, the estimated 8-year event-free survival (EFS) is 60.7% (±4%) and 8-year overall survival (OAS) is 72.6% (±3.7%) (Figure 1 ). These figures are within the range of contemporary outcome of childhood ALL therapy in the United States when all patients are accepted and included in the analysis and ethnicity is taken into account. [13] [14] [15] They indicate that selection of therapy by biological species using genotype and immunophenotype in these studies is feasible and acceptable although it may have no therapeutic advantage over the risk grouping used by others. Figure 2 describes EFS by biological category, as deter- Comparison of these features with those of patients without CNS relapse by Fisher's exact test indicated a significant association of CNS relapse with CNS 3 status (P = 0.0007), pro-B immunophenotype (P = 0.001) and DNA index Ͻ1.16 (P = 0.036). a 10 cells/l, no blasts reported.
Figure 1
Event-free and overall survival of 150 children with ALL registered on P8609/8904 pilot studies between 1986 and 1994. All patients are included in the analysis regardless of presenting condition or adherence to protocol.
Figure 2
Event-free survival of 147 children with ALL classified and treated according to genotype and immunophenotype; category E is excluded (only three children). Category A children have significantly better EFS than category B, C and D children by statistical testing.
mined by genotype and immunophenotype. Category E (B cell) is deleted because of its small number of patients. Estimated 8-year EFS for category A is 72.9% (±4.8%), for B is 50% (±15.8%), for C 56% (±8.3%) and for D 26.7% (±11.4%).
Comparison of EFS by log rank test demonstrates that children in category A had significantly better EFS than those in category B (P = 0.0004), category C (P = 0.032) and category D (P = Ͻ0.0001); those in C had significantly better EFS than those in D (P = 0.038). One of the three children in category E survives in first complete remission. The results suggest that the method of chemotherapy selection used in these studies did not overcome differences in treatment response among the biologic species of ALL as defined here.
The outcome of patients with T cell ALL is below current expectations. Of the 11 children with treatment failures, one had been withdrawn from treatment by a parent, one was nonadherent to protocol, two developed secondary AML and one died in remission of pneumonia. Either chance and small numbers, an inferior treatment regimen or both might account for the low EFS.
For purpose of comparison, our 132 patients with B-precursor ALL (categories A, B and C) were retrospectively grouped according to current POG criteria as described under Methods (Figure 3) . 12 Estimated 8-year EFS was 82% (±7.3%) for the POG good risk group, 68.9% (±5.9%) for the standard risk group, and 48.8% (±7.6%) for the poor risk group. The differences in EFS by log rank test were significant for good vs standard risk (P = 0.004), good vs poor risk (P = 0.003) and standard vs poor risk (P = 0.024). Our patients with B-precursor ALL were also grouped retrospectively in accordance with the Rome/NCI prognostic criteria (Figure 4) . 11 For standard risk patients the 8-year EFS was 69.1% (±6.9%), and for high risk 58.8% (±6.9%), a difference not significantly different (P = 0.18). This information suggests that for patients stratified and treated in our studies the POG criteria for prognostic risk are more predictive than the Rome/NCI criteria.
Ethnicity, gender and survival
In a previous study 14 of Texas children with ALL registered on SWOG/POG protocols from 1974 to 1985, African-American (AA) children and Mexican-American (MA) boys had significantly lower EFS than European-American (EA) children. In Figure 3 Event-free survival of 132 children with B-precursor ALL treated according to genotype and immunophenotype and retrospectively classified by POG ALINC 16 risk criteria. Differences between good and standard and between standard and poor risk are statistically significant.
Figure 4
Event-free survival of 132 children with B precursor ALL treated according to genotype and immunophenotype and retrospectively classified by Rome/NCI consensus criteria. The difference between standard and poor risk is not statistically significant. the present studies (Figure 5 ), the estimated 8-year EFS for EA children is higher than MA, 64.4% (±6.2%) vs 60.9% (±6.1%), but the difference is not statistically significant (P = 0.5). The 8-year EFS of AA children, 20% (±12.6%), is significantly less than that for EA children (P = 0.002); that of Latin-American (LA) children, 81.2% (±11.6%), is superior to that for EA children but not significantly so (P = 0.23). Figure 6 reveals that both EA and MA girls have higher 8-year EFS (76% (±8.5%); 71% (±8.1%)) than EA and MA boys (55.7% (±8.5%); 51.5% (±8.7%)). When MA and EA data are combined the gender difference is significant (P = 0.025), but not the ethnic difference (P = 0.5). This gender difference is not explained by variations in treatment categories and is consistent with outcome of treatment regimens based on prognostic risk factors. 16, 17 The results here suggest that selection of treatment based on our method of biologic categorization did not overcome this difference.
Leukemia
Figure 5
Event-free survival of 144 registered children classified by ethnicity as Mexican-American (MA), European-American (EA), Latin-American (LA) or African-American (AA). The difference between EA and AA children was statistically significant but not the differences between EA and MA or EA and LA children.
Figure 6
Event-free survival of 123 Mexican-American (MA) and European-American (EA) children by gender. The difference between EA and MA boys and girls is statistically significant by gender but not by ethnicity. In contrast to 1974 to 1985 experience there is no significant difference between MA and EA boys.
Survival after relapse
Survival after relapse was poor, except for the children with isolated CNS or testicular relapse, despite intensive chemotherapy with or without hematopoietic transplantation. Of 41 children with hematological relapse, with or without an extramedullary site, only 10 are alive, six in second remission and four in third to fifth remission. Four of five children with isolated CNS relapse, three of four with isolated testicular relapse and one with lymph node relapse survive in second remission. One child with visceral relapse and two of three with secondary AML have died.
Discussion
ALL is a genetic disorder of hematopoiesis and there is ample evidence that its genotype is a determinant of therapeutic response, as measured by survival and cure. [3] [4] [5] [6] [7] [8] How cure rate can be improved by therapy directed to a genetic species of ALL is best exemplified by B cell (SIg + ) ALL. It has a 30 to 35% DNA synthesis rate, the highest of any tumor, associated with a consistent genetic lesion, dysregulation of MYC gene. When it was treated with conventional common (B-precursor) ALL regimens it was rapidly fatal in most patients. 18 However, when high dosage intravenous antimetabolites and alkylating agents were initiated during remission induction and early remission, the cure rate increased to that of B-precursor ALL. 19 This supports the concept of aiming leukemia therapy at specific genetic lesions or their consequences.
When the pilot studies described here were initiated in 1986, factors such as age and initial WBC, the Rome consensus, 11 were largely used to stratify patients with ALL for risk of relapse and assignment to treatment. Based on the thought that the biologic species of ALL, as indicated by its genotype and immunophenotype, might better determine chemotherapy selection than clinical prognostic factors we attempted to categorize our patients by the biologic species of their ALL as determined by immunophenotype and chromosomal numbers and arrangements, without regard to clinical prognostic factors. We assigned patients to treatment programs in accordance with what appeared to be most effective for their species from available information. 7, 8 Early results for the three biologically defined categories of B-precursor ALL were encouraging and remain historically comparable to those of risk-directed therapy, indicating the feasibility and acceptability of employing this concept. Numbers of patients with B cell and T cell ALL (our categories D and E) are inadequate for historical comparison. Differences persisted in outcome among the biologic categories as they usually do among conventional risk defined groups. When we retrospectively classified our patients with B-precursor ALL by current POG risk criteria, significant differences in EFS were observed with the POG grouping as with our biologic categorization. On the other hand, when the Rome/NCI risk criteria were used for retrospective classification of the same patients there was no significant difference in EFS between the two Rome/NCI prognostic groupings. This is not surprising because POG includes genotypic and immunophenotypic features in their risk stratification while the Rome/NCI method uses only age and WBC. Prognostic factors depend on treatment and how it is chosen. 20 Differences in survival by gender and ethnicity reported with risk-directed therapy were also found in our patients. 16, 17 As with most pilot studies there were numerous and often unforeseen problems as we proceeded. To the inherent problem of relatively small numbers and heterogeneity of patients were added those of unsatisfactory chromosome analyses in a quarter of the leukemias and lack of protocol adherence in some patients. A major deficit was the unavailability of molecular genotyping by Southern blot, PCR or FISH during these studies, methods which often detect significant leukemiaassociated genetic anomalies in the absence of chromosomal changes. Particularly important is TEL-AML ALL, the most frequent and one of the most significant genotypes, which is usually identified by molecular genetic studies rather than identification of the corresponding t(12;21) chromosomal rearrangement. 13 In recent years the use of immunophenotyping to classify and select therapy for ALL has become customary. Different treatment protocols are devised for B-precursor, T cell and B cell ALL, and within B-precursor ALL, separate protocols for infantile ALL, which is often pro-B and associated with MLL (HRX) gene rearrangement. 21 As noted above, POG now uses cytogenetic information to modify risk classification while others have gone further by including molecular genotyping. 12, 13, 21, 22 A genetic classification has been proposed with the rationale that gene-targeted therapy will soon become available for testing and that knowledge of molecular genotype will facilitate the conduct of clinical trials, as well as the investigation of the etiology and epidemiology of ALL. 9 It should be noted that early response to therapy as denoted by clearing of leukemia from the bone marrow or reduction of PCR measured patient-specific leukemia clonal IgH/TCR gene transcripts in early remission have also been introduced into risk classification of ALL. 23, 24 Host factors such as gender, nutrition, socio-economic status, genetic polymorphism of drug metabolizing enzymes and ethnicity also appear to have prognostic significance. 20 Any classification scheme for selection of treatment may need to take into account some or all of these factors, as well as the genotype of leukemia in order to provide treatment optimally tailored to each patient.
Because of the hazardous sequelae of central nervous system (CNS) radiation, the improved efficacy of systemic and intrathecal chemotherapy in prevention of CNS relapse, and the high cure rate of isolated CNS relapse with contemporary treatment, CNS radiation was avoided in these studies except for one patient with recurrent CNS 2 status. 10 The low frequency of isolated CNS relapse in our studies (3%) suggests the effectiveness of the systemic and intrathecal chemotherapy schedules for preventing CNS leukemia. However, the two out of four incidences of CNS relapse in patients with initial CNS 3 status argue for additional preventive CNS therapy in such instances. The significant association of CNS relapse with pro-B immunophenotype and DNA index Ͻ1.16 and the marginal association with age Ͻ10 years, CNS 2 status and initial WBC Ͼ100 × 10 9 /l also raises questions. Larger studies with numbers appropriate for multivariate statistical analysis are needed to resolve them.
Only three survivors appear to have serious late adverse sequelae; one with personality change following asparaginase-induced cortical vein thrombosis, one with chronic hepatitis C and one disabled with severe osteonecrosis who was extremely obese at diagnosis and remained so. The absence of late neurologic sequelae related to CNS therapy might be due not only to omission of cranial irradiation but also possibly to the separation of systemic and intrathecal methotrexate and cytarabine administration by at least 1 week.
Compared to previous experience in south Texas, 14 the difference in EFS between EA and MA children narrowed, largely because of better EFS in MA boys. AA children continued to have significantly reduced EFS, in contrast to recent experience reported from St Jude Children's Research Hospital, Memphis. 25 Of relevant interest is the recent report of the Children's Cancer Group 15 regarding ethnicity and survival of 8762 children treated for ALL between 1983 and 1995. Children classified as Hispanic or African-American had significantly less survival than those classified as Caucasian or Asian.
Although children with isolated CNS or testicular relapse treated with intensive chemotherapy and radiotherapy have a high rate of EFS and probable cure, 10, 26, 27 those with hematological relapse more often die despite intensive chemotherapy with or without hematopoietic transplants. 28 This again emphasizes that prevention of first relapse of ALL is essential when cure is the goal.
